A |
KRAS MUT (G12C) |
KRAS WT, NRAS WT, BRAF WT |
Pelvic-infiltrating, inoperable rectal cancer. No distant metastasis. |
The absence of distant metastases is associated with low abundance of circulating tumor DNA (ctDNA). |
B |
KRAS MUT (G13D) |
KRAS WT, NRAS WT, BRAF WT |
Left colon cancer with loco-regional disease. |
The absence of distant metastases is associated with low abundance of circulating tumor DNA (ctDNA). |
C |
KRAS MUT (G12V) |
KRAS WT, NRAS WT, BRAF WT |
Left colon cancer with subcentimetric nodal disease. |
The absence of distant metastases is associated with low abundance of circulating tumor DNA (ctDNA). |
D |
NRAS MUT (Q61H) |
KRAS WT, NRAS WT, BRAF WT |
Left colon cancer with multiple subcentimetric liver metastases. |
Low MAF for this mutation on ctDNA (predicted sensitivity is optimal for MAF > 5%). The liquid biopsy performed at disease progression (tumor burden increased) confirmed NRAS mutation. |
E |
BRAF MUT (V600E) |
KRAS WT, NRAS WT, BRAF WT |
Right colon cancer with multiple centimetric lung metastases. |
Patient with non-liver metastatic disease and a low burden of disease. Low MAF for this mutation on ctDNA (predicted sensitivity is optimal for MAF > 5%). |
F |
KRAS WT, NRAS WT, BRAF WT |
NRAS MUT (G13D) |
Nodal-limited recurrence of left colon cancer. |
The relapsed cancer is enriched with NRAS mutant cells, that were missed on tissue analysis. |